References
1. India State-Level Disease
Burden Initiative Cancer Collaborators. The burden of cancers and their
variations across the states of India: the Global Burden of Disease
Study 1990-2016. Lancet Oncol. 2018 Oct;19(10):1289–306.
2. Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C,
Taylor C, Arriagada R, et al. Effect of radiotherapy after
breast-conserving surgery on 10-year recurrence and 15-year breast
cancer death: meta-analysis of individual patient data for 10,801 women
in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707–16.
3. EBCTCG (Early Breast
Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C,
Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and
axillary surgery on 10-year recurrence and 20-year breast cancer
mortality: meta-analysis of individual patient data for 8135 women in 22
randomised trials. Lancet. 2014 Jun 21;383(9935):2127–35.
4. Punglia RS, Saito AM,
Neville BA, Earle CC, Weeks JC. Impact of interval from breast
conserving surgery to radiotherapy on local recurrence in older women
with breast cancer: retrospective cohort analysis. BMJ. 2010 Mar
2;340:c845.
5. Munshi A, Ganesh T, Mohanti
BK. Radiotherapy in India: History, current scenario and proposed
solutions. Indian J Cancer. 2019 Oct;56(4):359–63.
6. Lam J, Cook T, Foster S,
Poon R, Milross C, Sundaresan P. Examining Determinants of Radiotherapy
Access: Do Cost and Radiotherapy Inconvenience Affect Uptake of
Breast-conserving Treatment for Early Breast Cancer? Clin Oncol . 2015
Aug;27(8):465–71.
7. Cohen L. Radiotherapy in
breast cancer. I. The dose-time relationship theoretical considerations.
Br J Radiol. 1952 Dec;25(300):636–42.
8. Yarnold J, Ashton A, Bliss
J, Homewood J, Harper C, Hanson J, et al. Fractionation sensitivity and
dose response of late adverse effects in the breast after radiotherapy
for early breast cancer: long-term results of a randomised trial.
Radiother Oncol. 2005 Apr;75(1):9–17.
9. Owen JR, Ashton A, Bliss
JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy
fraction size on tumour control in patients with early-stage breast
cancer after local tumour excision: long-term results of a randomised
trial. Lancet Oncol. 2006 Jun;7(6):467–71.
10. Whelan TJ, Pignol JP,
Levine MN. Are Three Weeks of Whole-Breast Radiotherapy as Good as Five
Weeks in Early Breast Cancer?–10 Year Follow-Up in the Canadian Trial
of Hypofractionated …. Breast Care [Internet]. 2010;
Available from: http://www.karger.com/Article/Abstract/319790
11. Haviland JS, Mannino M,
Griffin C, Porta N, Sydenham M, Bliss JM, et al. Late normal tissue
effects in the arm and shoulder following lymphatic radiotherapy:
Results from the UK START (Standardisation of Breast Radiotherapy)
trials. Radiother Oncol [Internet]. 2017 Nov 15; Available from:
http://dx.doi.org/10.1016/j.radonc.2017.10.033
12. Haviland JS, Owen JR,
Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK
Standardisation of Breast Radiotherapy (START) trials of radiotherapy
hypofractionation for treatment of early breast cancer: 10-year
follow-up results of two randomised controlled trials. Lancet Oncol.
2013 Oct;14(11):1086–94.
13. Valle LF, Agarwal S,
Bickel KE, Herchek HA, Nalepinski DC, Kapadia NS. Hypofractionated whole
breast radiotherapy in breast conservation for early-stage breast
cancer: a systematic review and meta-analysis of randomized trials.
Breast Cancer Res Treat. 2017 Apr;162(3):409–17.
14. Courdi A, Ortholan C,
Hannoun-Lévi J-M, Ferrero J-M, Largillier R, Balu-Maestro C, et al.
Long-term results of hypofractionated radiotherapy and hormonal therapy
without surgery for breast cancer in elderly patients. Radiother Oncol.
2006 May;79(2):156–61.
15. FAST Trialists group,
Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, et al. First
results of the randomised UK FAST Trial of radiotherapy
hypofractionation for treatment of early breast cancer (CRUKE/04/015).
Radiother Oncol. 2011 Jul;100(1):93–100.
16. Sanz J, Zhao M, Rodríguez
N, Granado R, Foro P, Reig A, et al. Once-Weekly Hypofractionated
Radiotherapy for Breast Cancer in Elderly Patients: Efficacy and
Tolerance in 486 Patients. Biomed Res Int. 2018 Mar 15;2018:8321871.
17. Dragun AE, Ajkay NJ,
Riley EC, Roberts TL, Pan J, Rai SN, et al. First Results of a Phase 2
Trial of Once-Weekly Hypofractionated Breast Irradiation (WHBI) for
Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2017 Jul
1;98(3):595–602.
18. Brunt AM, Wheatley D,
Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity
associated with a 1-week schedule of whole breast radiotherapy compared
with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
Radiother Oncol. 2016 Jul;120(1):114–8.
19. Bartelink H, Maingon P,
Poortmans P, Weltens C, Fourquet A, Jager J, et al. Whole-breast
irradiation with or without a boost for patients treated with
breast-conserving surgery for early breast cancer: 20-year follow-up of
a randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):47–56.
20. Franco P, Zeverino M,
Migliaccio F, Cante D, Sciacero P, Casanova Borca V, et al.
Intensity-modulated and hypofractionated simultaneous integrated boost
adjuvant breast radiation employing statics ports of tomotherapy
(TomoDirect): a prospective phase II trial. J Cancer Res Clin Oncol.
2014 Jan;140(1):167–77.
21. Van Parijs H, Miedema G,
Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, et al. Short course
radiotherapy with simultaneous integrated boost for stage I-II breast
cancer, early toxicities of a randomized clinical trial. Radiat Oncol.
2012 Jun 1;7:80.
22. Mondal D, Julka PK,
Sharma DN, Jana M, Laviraj MA, Deo SV, et al. Accelerated
hypofractionated adjuvant whole breast radiation with simultaneous
integrated boost using volumetric modulated arc therapy for early breast
cancer: A phase I/II dosimetric and clinical feasibility study from a
tertiary cancer care centre of India. J Egypt Natl Canc Inst. 2017
Mar;29(1):39–45.
23. Shin SM, No HS, Vega RM,
Fenton-Kerimian M, Maisonet O, Hitchen C, et al. Breast, chest wall, and
nodal irradiation with prone set-up: Results of a hypofractionated trial
with a median follow-up of 35 months. Pract Radiat Oncol. 2016
Jul;6(4):e81–8.
24. De Rose F, Fogliata A,
Franceschini D, Navarria P, Villa E, Iftode C, et al. Phase II trial of
hypofractionated VMAT-based treatment for early stage breast cancer:
2-year toxicity and clinical results. Radiat Oncol. 2016 Sep
17;11(1):120.
25. Cooper BT,
Formenti-Ujlaki GF, Li X, Shin SM, Fenton-Kerimian M, Guth A, et al.
Prospective Randomized Trial of Prone Accelerated Intensity Modulated
Breast Radiation Therapy With a Daily Versus Weekly Boost to the Tumor
Bed [Internet]. Vol. 95, International journal of radiation
oncology, biology, physics. 2016. p. 571–8. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/27131077
26. Cante D, Petrucci E,
Sciacero P, Piva C, Ferrario S, Bagnera S, et al. Ten-year results of
accelerated hypofractionated adjuvant whole-breast radiation with
concomitant boost to the lumpectomy cavity after conserving surgery for
early breast cancer. Med Oncol. 2017 Sep;34(9):152.
27. Paelinck L, Gulyban A,
Lakosi F, Vercauteren T, De Gersem W, Speleers B, et al. Does an
integrated boost increase acute toxicity in prone hypofractionated
breast irradiation? A randomized controlled trial. Radiother Oncol. 2017
Jan;122(1):30–6.
28. Versmessen H, Vinh-Hung
V, Van Parijs H, Miedema G, Voordeckers M, Adriaenssens N, et al.
Health-related quality of life in survivors of stage I-II breast cancer:
randomized trial of post-operative conventional radiotherapy and
hypofractionated tomotherapy [Internet]. Vol. 12, BMC cancer. 2012.
p. 495. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/23098579
29. Coles CE, Griffin CL,
Kirby AM, Haviland JS, Titley JC, Benstead K, et al. Dose escalated
simultaneous integrated boost radiotherapy for women treated by breast
conservation surgery for early breast cancer: 3-year adverse effects in
the IMPORT HIGH trial (CRUK/06/003) [Internet]. San Antonio Breast
Cancer Symposium; 2018 Dec 6 [cited 2018 Nov 30]; San Antionio,
Texas, USA. Available from:
https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_527&terms=
30. Mukesh MB, Duke S,
Parashar D, Wishart G, Coles CE, Wilson C. The Cambridge post-mastectomy
radiotherapy (C-PMRT) index: a practical tool for patient selection.
Radiother Oncol. 2014 Mar;110(3):461–6.
31. Feng M, Moran JM,
Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and
validation of a heart atlas to study cardiac exposure to radiation
following treatment for breast cancer. Int J Radiat Oncol Biol Phys.
2011 Jan 1;79(1):10–8.
32. Yi SK, Hall WH, Mathai M,
Dublin AB, Gupta V, Purdy JA, et al. Validating the RTOG-endorsed
brachial plexus contouring atlas: an evaluation of reproducibility among
patients treated by intensity-modulated radiotherapy for head-and-neck
cancer. Int J Radiat Oncol Biol Phys. 2012;82(3):1060–4.
33. START Trialists’ Group,
Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, et al. The
UK Standardisation of Breast Radiotherapy (START) Trial A of
radiotherapy hypofractionation for treatment of early breast cancer: a
randomised trial. Lancet Oncol. 2008 Apr;9(4):331–41.
34. Kundu S, Chakraborty S,
Chatterjee S, Das S, Achari RB, Mukhopadhyay J, et al. De-Identification
of Radiomics Data Retaining Longitudinal Temporal Information. J Med
Syst. 2020 Apr 2;44(5):99.
35. Brunt AM, Haviland J,
Sydenham M, Algurafi H, Alhasso A, Bliss P, et al. FAST Phase III RCT of
Radiotherapy Hypofractionation for Treatment of Early Breast Cancer:
10-Year Results (CRUKE/04/015). In: Annual Meeting of the American
Society of Radiation Oncology. American Society of Radiation Oncology;
2018. p. 1603–4.